CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 116 enrolled
Drug / intervention
Etafilcon A Design 1 (Test 1) +2 moredevice
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Age 18–55 years (inclusive)
  • ✓Myopic refraction −1.00 to −6.00 D in each eye
  • ✓Astigmatism ≤−1.50 DC in each eye
  • ✓Best corrected visual acuity ≥20/25 in each eye
Key exclusion· 15
  • ✕Working in advertising, public relations, marketing, market research, or contact lens/eyewear manufacturing/sales
  • ✕Paid market research participation within 3 months
  • ✕Pregnant or breast feeding
  • ✕Diabetes

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02801396
NCT02801396N/ACompleted
CompareCT.gov

Clinical Evaluation of Investigational Contact Lenses

Johnson & Johnson Vision Care, Inc.·interventional·Posted Jun 15, 2016·Updated Jul 11, 2017

In Brief

A clinical study evaluating Etafilcon A Design 1 (Test 1), Etafilcon A Design 2 (Test 2), and 1 other intervention for Visual Acuity. Completed, enrolled 116 participants across 1 site.

Detailed Summary

Single-visit, unmasked, non-dispensing study where subjects will wear three different lenses bilaterally in one visit, each lens being worn for approximately 30-60 minutes. Subjects will complete a questionnaire for each study lens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVisual Acuity
CountriesHong Kong
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 15, 2016
Enrollment StartApr 24, 2016
Primary CompletionMay 22, 2016
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 10.0 years ago

Interventions

Etafilcon A Design 1 (Test 1)device

Etafilcon A Design 2 (Test 2)device

Etafilcon A (Control)device